29.84
0.04 (0.13%)
| Previous Close | 29.80 |
| Volume | 1,147,715 |
| Price / Sales | 122.57 |
| Price / Book | 7.26 |
| 52 Weeks Range |
| Operating Margin (TTM) | -130,369.45% |
| Diluted EPS (TTM) | -3.35 |
| Total Debt/Equity (MRQ) | 3.82% |
| Current Ratio (MRQ) | 19.49 |
| Operating Cash Flow (TTM) | -279.75 M |
| Levered Free Cash Flow (TTM) | -171.41 M |
| Return on Assets (TTM) | -32.62% |
| Return on Equity (TTM) | -51.95% |
News Mood
-
Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says
09 Nov, 2:06PM
-
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
09 Nov, 6:01AM
-
Viridian Therapeutics Inc (VRDN) (Q3 2026) Earnings Call Highlights: Lumvoa's Strong Debut With ...
07 Nov, 9:02PM
AIStockmoo Score
| Value 30% | -0.7 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Earns below its cost of capital. Returns on capital rising. info | |
| Timing 30% | 1.4 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Somewhat below its 52-week high. info | |
| Price and its moving averages are lined up in an uptrend. Its main moving average is rising. Close to its rising moving average. Volume is heavier on up days. info | |
| Candle Patterns info | NA |
| Above its medium-term trend line. info | |
| Sentiment 20% | 0.5 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Smart Money 20% | 3.0 |
| Insider Activity info | NA |
| Institutions net +3.87% of shares in their latest 13F filings: 136 holders increased, 88 decreased (quarter to 30 Sep 2026). info | |
| Short interest -12.7% from 31 Aug to 30 Oct 2026, 9.1 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is high against its 52-week average. Up over 5 years. info | |
| Trend up on all three terms. Short-term momentum rising. info | |
| Price is near resistance. info | |
| Final Score | 0.87 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Viridian Therapeutics, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| VRDN | - | - | - | 7.26 |
| TRML | 1 B | - | - | 4.76 |
| OBIO | - | - | - | 57.25 |
| VRCA | - | - | - | 15.60 |
| TECH | - | 0.44% | - | 5.28 |
| ABEO | - | - | - | 1.10 |
Select this tab to load the latest available analysis.
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 114.61% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 126.23%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 136 | 20,191,430 |
| Decreased | 88 | 17,420,004 |
| New | 45 | 7,039,728 |
| Sold out | 25 | 5,397,253 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 17,042,236 | 9.1 |
| 15 Oct 2026 | 18,002,311 | 8.0 |
| 30 Sep 2026 | 17,965,668 | 8.9 |
| 15 Sep 2026 | 19,465,251 | 15.7 |
| 31 Aug 2026 | 19,511,841 | 16.6 |
| 14 Aug 2026 | 19,026,492 | 9.1 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 09 Nov 2026 | Yahoo Finance |
Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says
Jefferies sees VRDN-008 as a potential best-in-class FcRn inhibitor, with its extended half-life supporting eight-week dosing and offering a competitive advantage in a market dominated by less convenient treatment schedules. The broker views Viridian Therapeutics (NASDAQ:VRDN)'s decision to… |
| 09 Nov 2026 | Yahoo Finance |
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
WALTHAM, Mass., November 09, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008… |
| 07 Nov 2026 | Yahoo Finance |
Viridian Therapeutics Inc (VRDN) (Q3 2026) Earnings Call Highlights: Lumvoa's Strong Debut With ...
Viridian Therapeutics Inc (VRDN) kicked off its Lumvoa launch with more than 100 patients treated and over $955 million in cash to fund operations through profitability. |
| 06 Nov 2026 | Yahoo Finance |
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
WALTHAM, Mass., November 06, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present… |
| 06 Nov 2026 | Yahoo Finance |
Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Viridian Therapeutics (VRDN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
| 04 Nov 2026 | Yahoo Finance |
Viridian Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Viridian Therapeutics, Inc.'s Q3 2026 earnings call… |
| 04 Nov 2026 | Yahoo Finance |
Viridian Therapeutics (VRDN) Stock Looks Overvalued Even With Its New Launch
Viridian Therapeutics has had a powerful three year run, yet the real puzzle for investors is whether the current share price still lines up with what its balance sheet supports. With fresh product launches and pipeline progress now in the mix, the question is how far the stock has moved relative… |
| 04 Nov 2026 | Yahoo Finance |
What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
Viridian Therapeutics (NASDAQ:VRDN) reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment’s first quarter on the market, with more than 100 patients having received at least one infusion by Sept. 30. President and CEO Steve Mahoney said the launch exceeded t… |
| 04 Nov 2026 | Yahoo Finance |
Viridian (VRDN) Q3 2026 Earnings Call Transcript
First full quarter of Lumvoa sales beat expectations as patient starts accelerated. |
| 04 Nov 2026 | Yahoo Finance |
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +19.80% and +348.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 04 Nov 2026 | Yahoo Finance |
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
WALTHAM, Mass., November 04, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the… |
| 02 Nov 2026 | Yahoo Finance |
A $2 Billion Fund Bought These 3 Stocks Last Quarter
Key TakeawaysA $2 billion fund’s latest 13F shows its three biggest adds in the quarter ended June 30 were Viridian Therapeutics, Travere Therapeutics, and Legend Biotech. Analysts’ average price targets sit 47% to 111% above Friday’s close for the three stocks. |
| 27 Oct 2026 | Yahoo Finance |
How FDA Approval Will Impact Viridian Therapeutics Stock
Viridian Therapeutics received FDA approval in June 2026 for Lumvoa, an IGF-1R antibody for active and chronic Thyroid Eye Disease, following Phase III data showing meaningful clinical benefits with a 12-week, 5-infusion IV regimen. The approval gives Viridian Therapeutics its first commercial… |
| 20 Oct 2026 | Yahoo Finance |
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
WALTHAM, Mass., October 20, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial… |
| 16 Oct 2026 | Yahoo Finance |
Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base
Viridian Therapeutics has seen a mixed share price story in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$19.03 price tag adequately grounded in what the company is generating through its sales? Over the past 3 years the stock has… |
| 22 Sep 2026 | Yahoo Finance |
Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says
Viridian Therapeutics' (VRDN) Lumvoa is off to a "stronger start" than anticipated, RBC Capital Mark… |
| 02 Sep 2026 | Yahoo Finance |
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass., September 02, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside… |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |